Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 32 of 65 · 3114 articles
Tools that reliably measure self-care self-efficacy can help clinicians identify IBD patients who may benefit from extra self-management support. A brief, validated 10-item scale is practical for busy clinics and...
Patients and clinicians may notice fewer resources from a major drugmaker focused on a specific T‑cell antigen discovery effort for Crohn’s disease; researchers and investors should see this as a signal about how large...
News about large drugmakers’ pipelines and analyst optimism can affect future availability and development of therapies for IBD. Mentions of a drug (Tulisokibart) being developed for ulcerative colitis and Crohn’s may...
This research suggests a new way the gut could “remember” prior injury: lasting changes in the tissue scaffold (ECM) that may push stem cells toward pro‑inflammatory behavior and help explain recurring IBD flares.
The study points to CD226 (DNAM-1) being linked to inflammatory and interferon-driven programs in specific intestinal immune cells in Crohn's disease, which may be relevant to understanding disease mechanisms or...
Patients, clinicians, and payers may care because the analysis addresses the relative economic value of two approved biologic options (vedolizumab and risankizumab) for Crohn’s disease treatment in Italy and could...
Because having a sibling with Crohn's disease during childhood was linked to substantially higher risk of developing Crohn's later, and the study points to early-life microbiome differences and elevated faecal...
People with IBD might be interested because the study explores a new natural-product intervention that appears to reduce colitis severity in an animal model by activating the Nrf2 antioxidant pathway — a pathway already...
Achieving histologic or biochemical remission in addition to clinical and endoscopic remission was associated with substantially lower relapse risk in ulcerative colitis across multiple follow-up intervals, suggesting...
Non-invasive, inexpensive blood-derived ratios could offer easier, more frequent assessment of IBD activity than repeat endoscopy. This study evaluates several such ratios (CAR, PAR, NLR, FAR, Hb/CRP) against clinical...
Perianal fistulizing Crohn’s disease is difficult to treat and many patients don’t respond to available medical and surgical options. This trial tests an existing wound‑healing therapy (HBOT) in a formal controlled...
This trial tests whether a seaweed-derived fucoidan given with standard 5-ASA therapy can change biomarkers linked to mucosal healing (fecal calprotectin, fecal short-chain fatty acids) and stool consistency in people...
Researchers and patients tracking new IBD therapies may care because this is the first human study of a GlaxoSmithKline investigational drug aimed at colitis/ulcerative colitis — an early step that could lead to future...
Pouchitis is a common problem after colectomy with J‑pouch in ulcerative colitis and there are limited options to prevent it. If Aquamin® lowers inflammation or improves gut barrier measures, it could become a low‑risk...
The study identifies ABTB1 as a regulator that limits STAT3-driven Th17 differentiation and reduces severity in a mouse colitis model, suggesting a new molecular pathway relevant to IBD inflammation and a potential...
Researchers are exploring ferroptosis as a double-edged mechanism: preventing it may protect healthy gut lining in IBD, while inducing it might help treat colorectal cancer. Advances could lead to new biomarkers or...
Research linking ETBF to intestinal inflammation and colorectal cancer suggests better detection and targeted therapies for this microbe could eventually affect IBD management and cancer risk assessment.
The review helps patients, caregivers, clinicians, and researchers know which caregiver-impact PROMs have some validity evidence in pediatric chronic GI disorders and which tools still need more testing before widespread...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Visualized...
Fistulizing Crohn’s disease is a major complication where durable structural repair is hard to achieve. Regenerative cell-sheet approaches aim to rebuild tissue architecture rather than only suppress inflammation, which...
The study suggests electroacupuncture may reduce intestinal inflammation in a rat model of ulcerative colitis by enhancing epithelial autophagy and altering the gut microbiota—mechanisms relevant to IBD pathophysiology.
Non-invasive biomarkers can help detect and monitor IBD activity, distinguish IBD from other GI conditions, and potentially predict relapse—tools that may reduce need for invasive tests.
The paper suggests gut bacteria make an anti-inflammatory metabolite (NOP) that accumulates in IBD and reduces inflammatory responses in cells and multiple mouse colitis models, pointing to a potential microbiome-derived...
Patients diagnosed with IBD during or shortly after emergency hospital care had substantially worse 1-year outcomes in this large, population-based analysis — highlighting that late or emergency presentation is linked to...
The paper describes plant-derived compounds that reduced inflammation and partly corrected gut microbiome disturbances in lab and mouse models of colitis, suggesting a possible route to microbiome-targeted IBD therapies...
Researchers present a small platelet-related gene signature (TRIM22, TIMP1, RAC2) that may help understand UC biology and point toward blood-based biomarkers. If validated further, such markers might aid noninvasive...
The study describes a new molecular axis (Uhrf1 → PKM2 ubiquitination) that reduced inflammation and pyroptosis in IBD models and identifies a compound (EPT) that promotes this interaction — a potential early-stage...
Biomarker discordance is common in treat-to-target IBD care; understanding which tests reflect local gut inflammation versus systemic response can help avoid unnecessary treatment changes and guide targeted...
CDI is a serious infection that raises the risk of death for people with IBD. This study shows mortality linked to IBD+CDI changed over the last 25 years and that racial, geographic, and urban–rural disparities...
Fucosylation appears to influence intestinal barrier function, host–microbiota interactions, and immune responses — processes central to IBD pathogenesis. If validated, fucosylation-related biomarkers or therapies could...
PSC is closely linked with IBD (especially ulcerative colitis); understanding mechanisms that damage bile ducts could point to new future therapies or biomarkers.
If you or a patient is about to start infliximab for ulcerative colitis, routine blood counts may help identify those unlikely to respond to induction therapy; a high negative predictive value suggests these markers...
This study suggests a new, compact DNA-methylation biomarker that identifies accelerated aging in the colon linked to chronic inflammation (IBD) and pre-cancerous conditions. Such biomarkers could eventually help...
The study shows that mucosal CD3+ T‑cell density is higher in dogs with an IBD-like condition than in healthy dogs, suggesting mucosal T‑cell infiltration is part of the disease but may not reflect how sick an individual...
The study suggests that modifiable early-life factors (feeding, antibiotic exposure, activity, BMI, smoke exposure, delivery mode, diet) may influence the later risk of IBD, especially Crohn's disease, which could be...
The study suggests a traditional Chinese medicine formula can reduce disease signs in a mouse model of chronic relapsing ulcerative colitis and that its effects are mediated by changes in the gut microbiota and microbial...
A validated claims-based algorithm could enable larger, more efficient studies of fibrostenosis in Crohn’s disease using real-world data — helping researchers and clinicians better measure how often stricturing...
Researchers are exploring ways to prioritize who needs colonoscopy sooner; adding TCM features to prediction models might change triage performance. Patients and clinicians interested in pre-endoscopic risk tools or...
This registered randomized trial tests whether adding a specific intradermal acupuncture method to standard mesalazine treatment helps people with mild–moderately active ulcerative colitis reach clinical remission.
This trial tests a non-drug way (virtual reality medical-hypnosis content) to reduce pain and embarrassment during rectosigmoidoscopy — a common, sometimes poorly tolerated procedure in ulcerative colitis that patients...
A dietary multi-mineral supplement is being tested in a Phase 2 trial to see if it can improve symptoms, influence inflammation biomarkers, and help induce or maintain remission in people with ulcerative colitis.
The study reports an experimental coating that both protects a probiotic and provides antioxidant, anti-inflammatory effects in a mouse colitis model—an approach that, if validated in humans, could improve probiotic...
The study targets macrophage mitochondrial dysfunction, a mechanism linked to inflammation in ulcerative colitis, and demonstrates a nanodelivery approach that reduced colitis in mice—an approach that could inspire new...
A JAK inhibitor (upadacitinib) used for moderate–severe ulcerative colitis can cause neutropenia; this case report discusses how it was identified and managed, which matters for patients on the drug and clinicians...
Basal crypt dysplasia is easy to miss but linked to higher risk of advanced colorectal neoplasia in longstanding IBD. Improved recognition and use of p53 immunohistochemistry or complementary biomarkers could affect...
Cure8 found this source from nai500.com, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.
NUDT15 genotyping can identify people at high risk of severe thiopurine-induced myelosuppression; if cost-effective, testing could change how clinicians choose or dose thiopurines for IBD, potentially preventing serious...
The study suggests a natural seaweed-derived polysaccharide could modify gut bacteria and immune signaling in ways that reduced experimental colitis, which may interest people looking for microbiota-targeted dietary...
